Business Wire

CIRIUM

5.10.2022 09:01:49 CEST | Business Wire | Press release

Share
Vueling and Cirium Sign a Deal for Cirium Sky, to Dramatically Improve Airline Operational Performance

Vueling, an airline which forms part of IAG (International Airlines Group), has signed a landmark deal with Cirium, the aviation analytics company, to improve airline operational efficiencies through the Cirium Sky managed data warehouse and analytics solution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005079/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vueling and Cirium sign a deal for Cirium Sky, to dramatically improve airline operational performance (Photo: Business Wire)

The multi-year deal provides Vueling, with access to Cirium’s new data aviation warehouse and analytics capability.

This partnership will allow the airline to gain a unique insight from over 25 operational factors, and ultimately provide a best-in-traveller experience.

Cirium Sky will enable more effective flight planning, especially around disruption, to minimize delays for its customers.

Jeremy Bowen, Cirium CEO, said: “Our aviation data warehouse, Cirium Sky, is critical in supporting Vueling’s digital transformation initiatives and will enable the airline to improve flight operations, reduce travel delays and set the stage for operational excellence.”

Vueling is viewed by Cirium as the agile and innovative leader in IAG thanks to the implementation of several initiatives, including Vueling Transform, to unlock its full potential through digitization and low-cost leadership.

Oliver Iffert, Vueling Chief Operations Officer , said: “Coming out of the pandemic, Vueling is emerging even more efficient and competitive as we prioritize actionable insights backed by a wealth of data and context.”

“Data is key to assessing our operations and identifying ways to provide a passenger experience that stands out.”

“Using Cirium Sky, Vueling can plan flights more effectively and analyze flight delays based on accurate data. We will, as a result, drive a reduction in delays and minimize disruptions.”

The move to Cirium Sky transitions Vueling from using multiple data providers and data held in siloed systems to a single source of aviation data and analytics.

This strategic data and analytics partnership provides the airline with access to the industry’s largest data warehouse, which has a 360-degree view of flights, as well as prescriptive and predictive analytics to anticipate future operational challenges.

Added Bowen: “Improving operations is not only key for the traveller experience but also for tackling the liquidity issues and capacity recovery that airlines are facing in the wake of COVID-19.“

“By democratizing data and enabling smarter and faster decision making, airlines would see huge savings. We are delighted to partner with Vueling and drive value for their business.”

Cirium Sky is purpose-built to enable airlines, airports, financial institutions, aircraft manufacturers, and travel distributors to unlock the value in aviation data.

Find out more about Cirium Sky.

Ends

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com

About Vueling

Vueling, a company which forms part of IAG, is key in connectivity in Spain, the largest domestic market in Europe. For this winter 2022, the company has a network of more than 240 short and medium-haul routes in Europe, North Africa and the Middle East, which are operated with a fleet of Airbus A319, A320, A320neo and A321 models. In 2021, Vueling has won the World Airline Awards as the "Best Low Cost Airline in Europe".

As part of IAG, Vueling shares the vision of leading the field of sustainability within the global airline industry. That is why the company develops all its actions within the framework of the "Flightpath Net Zero" program, through which the goal of achieving net zero CO2 emissions in 2050 has been established.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005079/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release

£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release

Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye